The 109 references in paper Ya. Zverev Ph., V. Bryukhanov M., V. Lampatov V., A. Jaricov Yu., Я. Зверев Ф., В. Брюханов М., В. Лампатов В., А. Жариков Ю. (2009) “СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О РОЛИ ФИЗИКО-ХИМИЧЕСКИХ ФАКТОРОВ В ПАТОГЕНЕЗЕ КАЛЬЦИЕВОГО НЕФРОЛИТИАЗА // THE CURRENT VIEWS ON THE ROLE OF PHYSICO-CHEMICAL FACTORS IN PATHOGENESIS OF CALCIUM NEPHROLYTHIASIS” / spz:neicon:nefr:y:2009:i:1:p:39-50

1
Hess B. Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi. Ther Umsch 2003; 60 (2): 79-87
(check this in PDF content)
2
Reynolds TM. Chemical pathology, clinical investigation and management of nephrolithiasis. J Clin Pathol 2005; 58 (2): 134-140
(check this in PDF content)
3
Тиктинский ОЛ, Александров ВП. Мочекаменная бо­ лезнь. Питер, СПб., 2000; 53-91
(check this in PDF content)
4
Кадыров ЗА, Истратов ВГ, Сулейманов СИ. Некото­ рые вопросы этиологии и патогенеза мочекаменной болез­ ни. Урология 2006; (5): 98-101
(check this in PDF content)
5
Heilberg IP, Schor N. Renal stone disease: causes, evaluation and medical treatment. Arq Bras Endocrinol Metab 2006; 50 (4): 823-831
(check this in PDF content)
6
Lingeman J, Kahnoski R, Mardis H et al. Divergence between stone composition and urine supersaturation: clinical and laboratory implications. J Urol 1999; 161 (4): 1077-1081
(check this in PDF content)
7
Pak CY Physicochemical basis for formation of renal stones of calcium phosphate origin: calculation of the degree of saturation of urine with respect to brushite. J Clin Invest 1969; 48 (10): 1914-1922
(check this in PDF content)
8
Pak CY, Holt K. Nucleation and growth of brushite and calcium oxalate in urine of stone-formers. Metabolism 1976; 25 (6): 665-673
(check this in PDF content)
9
Brown CM, Purich DL. Physical-chemical processes in kidney stone formation. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. Raven Press, New York, 1992; 613-624
(check this in PDF content)
10
Asplin JR, Bushinsky DA, Singharetnam W et al. Relationship between supersaturation and crystal inhibition in hypercalciuric rats. Kidney Int 1997; 51 (3): 640-645
(check this in PDF content)
11
Nicar MJ, Hill K, Pak CY. A simple technique for assessing the propensity for crystallization of calcium oxalate and brushite in urine from the increment in oxalate or calcium necessary to elicit precipitation. Metabolism 1983; 32 (9): 906­ 910
(check this in PDF content)
12
Bushinsky DA, Parker WR, Asplin JR. Calcium phosphate supersaturation regulates stone formation in genetic hypercalciuric stone-forming rats. Kidney Int 2000; 57: 550-560
(check this in PDF content)
13
Tiselius HG. Estimated levels of supersaturation with calcium phosphate and calcium oxalate in the distal tubule. Urol Res 1997; 25 (2): 153-159
(check this in PDF content)
14
Toblli JE, Angerosa M, Stella I et al. Urinary calcium oxalate supersaturation beyond nephrolithiasis. Relationship with tubulointerstitial damage. Medicina (B. Aires) 2003; 63 (2): 97-104
(check this in PDF content)
15
Robertson WG. Kidney models of calcium oxalate stone formation. Nephron Physiol 2004; 98 (2): 21-30
(check this in PDF content)
16
Pak CY Eanes ED, Puskin B. Spontaneous precipitation of brushite in urine: evidence that brushite is the nidus of renal stones originating as calcium phosphate. Proc Natl Acad Sci USA 1971; 68 (7): 1456-1460
(check this in PDF content)
17
Finlayson B. Physicochemical aspects of urolithiasis. Kidney Int 1978; 13 (5): 344-360
(check this in PDF content)
18
Carvalho M, Vieira MA. Changes in calcium oxalate crystal morphology as a function of supersaturation. Int Braz J Urol 2004; 30 (3): 205-209
(check this in PDF content)
19
Burns JR, Finlayson B. Changes in calcium oxalate morphology as function of concentration. Invest Urol 1980; 18 (2): 174-177
(check this in PDF content)
20
Parks JH, Coward M, Coe FL. Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int 1997; 51 (3): 894-900
(check this in PDF content)
21
Asplin JR, Parks J, Lingeman J et al. Supersaturation and stone composition in a network of dispersed treatment sites. J Urol 1998; 159 (6): 1821-1825
(check this in PDF content)
22
Pak CY, Galosy RA. Propensity for spontaneous nucleation of calcium oxalate. Quantitative assessment by urinary FPR-APR discriminant score. Am J Med 1980; 69 (5): 681-689
(check this in PDF content)
23
Bushinsky DA, Asplin JR, Grynpas MD et al. Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats. Kidney Int 2002; 61 (3): 975-987
(check this in PDF content)
24
Asplin JR, Parks JH, Coe FL. Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int 1997; 52 (6): 1602-1608
(check this in PDF content)
25
Bushinsky DA. Nephrolithiasis: site of the initial solid phase. J Clin Invest 2003; 111 (5): 602-605
(check this in PDF content)
26
Asplin JR, Parks JH, Chen MS et al. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int 1999; 56: 1505-1516
(check this in PDF content)
27
Asplin JR, Parks JH, Nakagawa Y, Coe FL. Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int 2002; 61: 1821-1829
(check this in PDF content)
28
Зверев ЯФ, Брюханов ВМ, Талалаева ОС и др. О роли процессов свободно-радикального окисления в раз­ витии экспериментального нефролитиаза. Нефрология 2008; 12 (1): 58-63
(check this in PDF content)
29
Брюханов ВМ, Зверев ЯФ, Лампатов ВВ и др. Фун­ кция почек в условиях экспериментального оксалатного не­ фролитиаза. Нефрология 2008; 12 (1): 69-74
(check this in PDF content)
30
Borghi L, Guerra A, Meschi T et al. Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers. Kidney Int 1999; 55: 1041-1050
(check this in PDF content)
31
Borghi L, Meschi T, Amato F et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996; 155 (3): 839-843
(check this in PDF content)
32
Bellizzi V, De Nicola L, Minutolo R et al. Effects of water hardness on urinary risk factors for kidney stones in patients with idiopathic nephrolithiasis. Nephron 1999; 81 (1): 66-70
(check this in PDF content)
33
Borghi L, Meschi T, Schianchi T et al. Urine volume: stone risk factor and preventive measure. Nephron 1999; 81 (1): 31-37
(check this in PDF content)
34
Whitson PA, Pietrzyk RA, Morukov BV, Sams CF. The risk of renal stone formation during and after long duration space flight. Nephron 2001; 89 (3): 264-270
(check this in PDF content)
35
Pietrzyk RA, Jones JA, Sams CF, Whitson PA. Renal stone formation among astronauts. Aviat Space Environ Med 2007; 78 (4): A9-A13
(check this in PDF content)
36
Whitson PA, Pietrzyk RA, Sams CF. Urine volume and its effects on renal stone risk in astronauts. Aviat Space Environ Med 2001; 72 (4): 368-372
(check this in PDF content)
37
Guerra A, Allegri F, Meschi T et al. Effects of urine dilution on quantity, size and aggregation of calcium oxalate crystals induced in vitro by an oxalate load. Clin Chem Lab Med 2005; 43 (6): 585-589
(check this in PDF content)
38
Guerra A, Meschi T, Allegri F et al. Concentrated urine and diluted urine: the effects of citrate and magnesium on the crystallization of calcium oxalate induced in vitro by an oxalate load. Urol Res 2006; 34 (6): 359-364
(check this in PDF content)
39
Parks JH, Goldfischer ER, Coe FL. Changes in urine volume accomplished by physicians treating nephrolithiasis. J Urol 2003; 169 (3): 863-866
(check this in PDF content)
40
Stitchantrakul W, Kochakarn W, Ruangraksa C, Domrangkitchaiporn S. Urinary risk factors for recurrent calcium stone formation in Thai stone formers. J Med Assoc Thai 2007; 90 (4): 688-698
(check this in PDF content)
41
Ratan SK, Bhatnagar V, Mitra DK et al. Urinary citrate excretion in idiopathic nephrolithiasis. Indian Pediatrics 2002; 39: 819-825
(check this in PDF content)
42
Tiselius HG, Berg C, Fornander AM, Nilsson MA. Effects of citrate on the different phases of calcium oxalate crystallization. Scanning Microsc 1993; 7 (1): 381-389
(check this in PDF content)
43
Pak CY, Poindexter JR, Adams-Huet B, Pearle MS. Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 2003; 115 (1): 26-32
(check this in PDF content)
44
Domrongkitchaiporn S, Stitchantrakul W, Kochakarn W. Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion. Am J Kidney Dis 2006; 48 (4): 546-554
(check this in PDF content)
45
Chow K, Dixon J, Gilpin S et al. Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones. Kidney Int 2004; 65 (5): 1724-1730
(check this in PDF content)
46
Hess B, Jordi S, Zipperle L et al. Citrate determines calcium oxalate crystallization kinetics and crystal morphology- studies in the presence of Tamm-Horsfall protein of a healthy subject and a severely recurrent calcium stone former. Nephrol Dial Transplant 2000; 15 (3): 366-374
(check this in PDF content)
47
Schwille PO, Schmied A, Manoharan M. Is calcium oxalate nucleation in postprandial urine of males with idiopathic recurrent calcium urolithiasis related to calcium phosphate nucleation and the intensity of stone formation? Studies allowing insight into a possible role of urinary free citrate and protein. Clin Chem Lab Med 2004; 42 (3): 283-293
(check this in PDF content)
48
Kulaksizoglu S, Sofikerim M, Cevik C. Impact of various modifiers on calcium oxalate crystallization. Int J Urol 2007; 14 (3): 214-218
(check this in PDF content)
49
Huijgaard I, Tiselius HG. The effects of citrate and urinary macromolecules on the aggregation of hydroxyapatite crystals in solutions with a composition similar to that in the distal tubule. Urol Res 1998; 26 (2): 89-95
(check this in PDF content)
50
Greischar A, Nakagawa X Coe FL. Influence of urine pH and citrate concentration on the upper limit of metastability for calcium phosphate. J Urol 2003; 169 (3): 867-870
(check this in PDF content)
51
Messa P, Mioni G, Paganin L et al. Urinary citrate, bone resorption and intestinal alkali absorption in stone formers with fasting hypercalciuria. Scanning Microsc 1994; 8 (3): 531­ 538
(check this in PDF content)
52
Berg C. Alkaline citrate in prevention of recurrent calcium oxalate stones. Scand J Urol Nephrol Suppl 1990; 130: 1-83
(check this in PDF content)
53
Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest 2005; 115 (10): 2598-2608
(check this in PDF content)
54
Hassani MA, Hennequin C, Lacour B, Daudon M. Influence of urinary citrate levels on spontaneous calcium oxalate dehydrate crystalluria. Prog Urol 2005; 15 (4): 650-655
(check this in PDF content)
55
Kok DJ, Papapoulos SE, Blomen LJMJ, Bijvoet OLM. Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int 1988; 34: 346-350
(check this in PDF content)
56
Hennequin C, Lalanne V, Drueke T et al. Validation by image analysis of a turbidimetric method to study calcium oxalate crystallization. Clin Nephrol 1997; 48: 292-299
(check this in PDF content)
57
Byer K, Khan SR. Citrate provides protection against oxalate and calcium oxalate crystal induced oxidative damage to renal epithelium. J Urol 2005; 173 (2): 640-646
(check this in PDF content)
58
Weber DV, Coe FL, Parks JH, Tembe V. Urinary saturation measurements in calcium nephrolithiasis. Am Int Med 1979; 90: 180-184
(check this in PDF content)
59
Hamm LL, Hering-Smith KS. Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol Metab Clin North Am 2002; 31 (4): 885-893
(check this in PDF content)
60
Allie-Hamdulay S, Rodgers A. Prophylactic and therapeutic properties of a sodium citrate preparation for the potential management of calcium oxalate urolithiasis: randomized, placebo-controlled trial. Urol Res 2005; 33: 116­ 124
(check this in PDF content)
61
Rodgers A, Allie-Hamdulay S, Jackson G. Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor. Nephrol Dial Transplant 2006; 21 (2): 361-369
(check this in PDF content)
62
Qiu SR, Wierzbicki A, Orme CA et al. Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Natl Acad Sci USA 2004; 101 (7): 1811-1815
(check this in PDF content)
63
Qiu SR, Wierzbicki A, Salter EA et al. Modulation of calcium oxalate monohydrate crystallization by citrate through selective binding to atomic steps. J Am Chem Soc 2005; 127 (25): 9036-9044
(check this in PDF content)
64
Yoreo JJ, Qiu SR, Hoyer JR. Molecular modulation of calcium oxalate crystallization. Am J Physiol Renal Physiol 2006; 291 (6): F1123-F1131
(check this in PDF content)
65
Cupisti A, Morelli E, Lupetti S et al. Low urine citrate excretion as main risk factor for recurrent calcium oxalate nephrolithiasis in males. Nephron 1992; 61: 73-76
(check this in PDF content)
66
Yagisawa T, Chandhoke PS, Fan J. Metabolic risk factors in patients with first-time and recurrent stone formations as determined by comprehensive metabolic evaluation. Urology 1998; 52: 750-755
(check this in PDF content)
67
Fegan J, Khan SR, Poindexter J, Pak CY Gastrointestinal citrate absorption in nephrolithiasis. J Urol 1992; 147: 1212­ 1214
(check this in PDF content)
68
Hamm LL. Renal handling of citrate. Kidney Int 1990; 38: 728-735
(check this in PDF content)
69
Pajor CY Citrate transport by the kidney and intestine. Semin Nephrol 1999; 19: 195-200
(check this in PDF content)
70
He Y, Chen X, Yu Z et al. Sodium dicarboxylate cotransporter-1 expression in renal tissues and its role in rat experimental nephrolithiasis. J Nephrol (JN) 2004; 17 (1): 34­ 42
(check this in PDF content)
71
Okamoto N, Aruda S, Matsuzaki S et al. Association between renal sodium-citrate cotransporter (hNaDC-1) gene polymorphism and urinary citrate excretion in recurrent renal calcium stone formers and normal controls. Int J Urol 2007; 14 (4): 344-349
(check this in PDF content)
72
Спасов АА. Магний в медицинской практике. Отрок, Волгоград, 2006; 34-56
(check this in PDF content)
73
Labeeuw M, Pozet N, Zech P, Traeger J. Role of magnesium in the physiopathology and treatment of calcium renal lithiasis. Presse Med 1987; 16 (1): 25-27
(check this in PDF content)
74
Johansson G, Backman U, Danielson BG et al. Effects of magnesium hydroxide in renal stone disease. J Am Cell Nutr 1982; 1 (2): 179-185
(check this in PDF content)
75
Vagelli G, Calabrese G, Pratesi G et al. Magnesium hydroxide in idiopathic calcium nephrolithiasis. Minerva Urol Nefrol 1998; 50 (1): 113-114
(check this in PDF content)
76
Rushton HG, Spector M. Effects of magnesium deficiency on intratubular calcium oxalate formation and crystalluria in hyperoxaluric rats. J Urol 1982; 127 (3): 598-604
(check this in PDF content)
77
Спасов АА, Иежица ИН, Харитонова МВ и др. Экспе­ риментальное обоснование эффективности солей магния в коррекции экспериментального кальций-фосфатного не- фролитиаза. Нефрология 2008; 12 (3): 72-78
(check this in PDF content)
78
Lieske JC, Farell G, Deganello S. The effect of ions at the surface of calcium oxalate monohydrate crystals on cell- crystal interactions. Urol Res 2004; 32 (2): 117-123
(check this in PDF content)
79
Fetner CD, Barilla DE, Townsend J, Pak CY. Effects of magnesium oxide on the crystallization of calcium salts in urine in patients with recurrent nephrolithiasis. J Urol 1978; 120 (4): 399-401
(check this in PDF content)
80
Schwartz BF, Bruce J, Lesile S, Stoller ML. Rethinking the role of urinary magnesium in calcium urolithiasis. J Endourol 2001; 15 (3): 233-235
(check this in PDF content)
81
Massey L. Magnesium therapy for nephrolithiasis. Magnesium Res 2005; 18 (2): 123-126
(check this in PDF content)
82
Schwille PO, Schmiedl A, Herrmann U et al. Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. Urol Res 1999; 27 (2): 117-126
(check this in PDF content)
83
Jaipakdu S, Prasongwatana V, Premgamone A et al. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients. J Med Assoc Thai 2004; 87 (3): 255-263
(check this in PDF content)
84
Zerwekh JE, Odvina CV, Wuermser LA, Pak CY Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest. J Urol 2007; 177 (6): 2179-2184
(check this in PDF content)
85
Grases F, Costa-Bauza A. Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment. Anticancer Res 1999; 19 (5A): 3717-3722
(check this in PDF content)
86
Grases F, March JG, Prieto RM et al. Urinary phytate in calcium oxalate stone formers and healthy people-dietary effects on phytate excretion. Scand J Urol Nephrol 2000; 34 (3): 162-164
(check this in PDF content)
87
Grases F, Garcia-Gonzalez R, Torres JJ, Llobera A. Effects of phytic acid on renal stone formation in rats. Scand J Urol Nephrol 1998; 32 (4): 261-265
(check this in PDF content)
88
Grases F, Isern B, Sanchis P et al. Phytate acts as an inhibitor in formation of renal calculi. Front Biosci 2007; 12: 2580-2587
(check this in PDF content)
89
Saw NK, Chow K, Rao PN, Kavanagh JP. Effects of inositol hexaphosphate (phytate) on calcium binding, calcium oxalate crystallization and in vitro stone growth. J Urol 2007; 177 (6): 2366-2370
(check this in PDF content)
90
Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 1962; 203: 671-675
(check this in PDF content)
91
Moochhala SH, Sayer JA, Carr G, Simmons NL. Renal calcium stones: insights from the control of bone mineralization. Exp Physiol 2008; 93 (1): 43-49
(check this in PDF content)
92
Russell RG. Metabolism of inorganic pyrophosphate (PPi). Arthritis Rheum 1976; 19 (3): 465-478
(check this in PDF content)
93
Laminski NA, Meyers AM, Sonnekus MI, Smyth AE. Prevalence of hypocitraturia and hypopyrophosphaturia in recurrent calcium stone formers: as isolated defects or associated with other metabolic abnormalities. Nephron 1990; 56: 379-386
(check this in PDF content)
94
Baumann JM, Bisaz S, Felix R et al. The role of inhibitors and other factors in the pathogenesis of recurrent calcium- containing renal stones. Clin Sci Mol Med 1977; 53: 141-148
(check this in PDF content)
95
Wikstrom B, Danielson BG, Ljunghall S et al. Urinary pyrophosphate excretion in renal stone formers with normal and impaired renal acidification. World J Urol 1983; 1: 150-154
(check this in PDF content)
96
Roberts NB, Dutton J, Helliwell T et al. Pyrophosphate in synovial fluid and urine and its relationship to urinary risk factors for stone disease. Ann Clin Biochem 1992; 29: 529-534
(check this in PDF content)
97
Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973; 11: 269-280
(check this in PDF content)
98
Grases F, Ramis M, Costa-Bauza A. Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization. Comparison with the action of other polyphosphates. Urol Res 2000; 28 (2): 136-140
(check this in PDF content)
99
March JG, Simonet BM, Grases F. Determination of pyrophosphate in renal calculi and urine by means of an enzymatic method. Clin Chim Acta 2001; 314: 187-194
(check this in PDF content)
100
Costa-Bauza A, Barcelo C, Perello J, Grases F. Synergism between the brushite and hydroxyapatite urinary crystallization inhibitors. Int Urol Nephrol 2002; 34: 447-451
(check this in PDF content)
101
Nouwen EJ, De Broe ME. Human intestinal versus tissue-nonspecific alkaline phosphatase as complementary urinary markers for the proximal tubule. Kidney Int Suppl 1994; 47: S43-S51
(check this in PDF content)
102
Harahap AR, Goding JW. Distribution of the murine plasma cell antigen PC-1 in non-lymphoid tissues. J Immunol 1988; 141: 2317-2320
(check this in PDF content)
103
Goding JW, Grobben B, Slegers H. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta 2003; 1638: 1-19
(check this in PDF content)
104
Vekaria RM, Shirley DG, Sevigny J, Unwin RJ. Immunolocalization of ectonucleotidases along the rat nephron. Am J Physiol Renal Physiol 2006; 290: F550-F560
(check this in PDF content)
105
Vekaria RM, Unwin RJ, Shirley DG. Intraluminal ATP concentrations in rat renal tubules. J Am Soc Nephrol 2006; 17: 1841-1847
(check this in PDF content)
106
Carr G, Sayer JA, Simmons NL. Expression and localization of the pyrophosphate transporter, ANK, in murine kidney cells. Cell Physiol Biochem 2007; 20: 507-516
(check this in PDF content)
107
Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000; 289: 265-270
(check this in PDF content)
108
Arrabal MM, Diaz de la Guardia FV, Jimenez PA et al. The treatment of renal lithiasis with biphosphonates. Arch Esp Urol 2007; 60 (7): 745-754
(check this in PDF content)
109
Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturateion in genetic hypercalciuric rats. Kidney Int 1999; 55 (1): 234-243 Поступила в редакцию 22.10.2008 г. Принята в печать 10.02.2009 г.
(check this in PDF content)